Formulations for treating fine lines and wrinkles and uses thereof

Abstract

Disclosed herein is a cosmetic composition comprising a Swertia japonica extract, hyaluronic acid and a retinoid, and a method for reducing fine lines and / or wrinkles and / or smoothing the skin by topically applying the cosmetic composition to the skin. The cosmetic composition comprises about 0.005% to about 0.500% by weight of a Swertia japonica extract, about 0.005% to about 1.00% by weight of a retinoid, and about 0.001% to about 2.0% by weight of hyaluronic acid. The cosmetic composition is applied to the skin of the neck and / or face in the morning, evening, or both, in the form of a cream or serum.

Description

[Technical field]

[0001] This application claims the benefit of priority to U.S. Patent Application No. 63 / 314,806, filed February 28, 2022, the disclosure of which is incorporated herein by reference in its entirety. Disclosed herein is a cosmetic composition containing Swertia chirata extract, hyaluronic acid, and a retinoid, which act together to improve the appearance of fine lines and wrinkles, as well as smooth the skin. Summary of the Invention

[0002] One general aspect of the present invention includes a cosmetic composition comprising an extract of Swertia japonica, hyaluronic acid, and a retinoid. In this embodiment, the composition may comprise from about 0.005% to about 0.500% by weight of the extract of Swertia japonica. In this embodiment, the composition may comprise from about 0.005% to about 1.00% by weight of the retinoid. In this embodiment, the composition may comprise from about 0.001% to about 2.0% by weight of hyaluronic acid. In one embodiment of the present invention, the cosmetic composition comprises about 0.005% to about 0.500% by weight of Swertia japonica extract, about 0.005% to about 1.00% by weight of a retinoid, and about 0.001% to about 2.0% by weight of hyaluronic acid. In a preferred embodiment, the composition comprises about 0.030% by weight of Swertia japonica extract, about 0.070% by weight of a retinoid, and about 0.050% by weight of hyaluronic acid. In another preferred embodiment, the composition comprises about 0.030% by weight of Swertia japonica extract, about 0.110% by weight of a retinoid, and about 0.002% by weight of hyaluronic acid.

[0003] In certain embodiments of the invention, the retinoid is selected from retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene and tazarotene, and trifarotene. In a preferred embodiment, the retinoid is retinol. In one embodiment of the invention, the hyaluronic acid is a mixture of hyaluronic acids of different molecular weights. In this embodiment, the mixture may contain at least three different hyaluronic acids of different molecular weights. In some embodiments of the present invention, the cosmetic composition may also include a vitamin C compound. In a preferred embodiment, the vitamin C compound may be ascorbic acid or 3-O-ethyl ascorbic acid.

[0004] In one embodiment of the present invention, the cosmetic composition may comprise a chromenone of formula (I) or a salt thereof. [ka] (In the formula, R 1 and R 2 are the same or different, H, -(C=O)-R 7 , -C(=O)-OR 7 , linear or branched C 1 -C 20 -alkyl group, where alkyl is selected from the group consisting of oxygen, linear or branched C 3 -C 20 -Alkenyl group, linear or branched C 1 -C 20 -hydroxyalkyl or di- or polyhydroxyalkyl groups, the hydroxyl groups being attached to a primary or secondary carbon atom of the alkyl, the alkyl being optionally interrupted at least once by oxygen, C 3 -C 10 -Cycloalkyl group and C 3 -C 12 -Cycloalkenyl group (cyclic group is -CH 2 ) n -group, n=1 to 3), R 3 is H or linear or branched C 1 -C 20 -alkyl group, R4 is H or -OR 8 and R 5 and R 6are the same or different, H or -OH, linear or branched C 1 -C 20 - an alkyl group (wherein the alkyl group may be interrupted at least once by oxygen), linear or branched C 3 -C 20 -Alkenyl group, and linear or branched C 1 -C 20 -hydroxyalkyl groups, wherein the hydroxyl group is attached to a primary or secondary carbon atom of the alkyl, and the alkyl may be interrupted at least once by oxygen; R 7 is H, linear or branched C 1 -C 20 -alkyl group, where alkyl is selected from the group consisting of oxygen, linear or branched C 3 -C 20 -Alkenyl group, and linear or branched C 1 -C 20 -hydroxy-alkyl or di- or polyhydroxyalkyl groups, the hydroxyl groups being attached to a primary or secondary carbon atom of the alkyl, the alkyl being optionally interrupted at least once by oxygen, R 8 is H or linear or branched C 1 -C 20 -alkyl group)

[0005] In this embodiment, the cosmetic composition comprises about 0.1% to about 2.0% by weight of the compound of formula (I). In a preferred embodiment, the compound of formula (I) is dihydroxymethylchromenone. In one embodiment of the present invention, the cosmetic composition comprises at least 60% by weight of water. In some embodiments of the present invention, the cosmetic composition may be a cream or a serum. Another general aspect of the present invention includes a method of reducing fine lines and / or wrinkles and / or smoothing skin by topically administering a cosmetic composition to the skin. In this embodiment, the skin may be neck and / or facial skin. In this embodiment, the cosmetic composition may be applied to the forehead, lips, between the eyebrows, under the eyes, nasolabial folds, crow's feet, or combinations thereof. In this embodiment, the skin may be cleansed skin. In this embodiment, the cosmetic composition may be applied in the morning, at night, or both. [Brief description of the drawings]

[0006] [Figure 1] 1A-1B depict the improvement in fine lines and wrinkles between the glabellar lines, (A) shows the skin before application of the cosmetic composition, and (B) shows the skin immediately after application of the cosmetic composition. [Diagram 2] 1 depicts the improvement in fine lines and wrinkles on the forehead, (A) shows the skin before application of the cosmetic composition, and (B) shows the skin after 4 weeks of daily application of the cosmetic composition. [Diagram 3] FIG. 1 depicts the results of a questionnaire in subjects administered a cosmetic composition according to the methods disclosed herein. [Figure 4] FIG. 1 depicts the results of a questionnaire in subjects administered a cosmetic composition according to the methods disclosed herein. [Diagram 5] FIG. 1 depicts the results of a questionnaire in subjects administered a cosmetic composition according to the methods disclosed herein. [Figure 6] FIG. 1 depicts the results of a questionnaire in subjects administered a cosmetic composition according to the methods disclosed herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] The embodiments of the present invention are discussed in detail below. In describing the embodiments, specific terminology is used for clarity. However, the present invention is not intended to be limited to the specific terminology so selected. Although specific exemplary embodiments are discussed, it should be understood that this is done for illustrative purposes only. Those skilled in the art will appreciate that other components and configurations can be used without departing from the spirit and scope of the present invention. All references cited herein are incorporated by reference as if each were individually incorporated.

[0008] All parts and percentages are by weight unless otherwise indicated. As used herein, the term "about" refers to plus or minus 10% of the indicated value. Unless otherwise specified or evident from the context, percentages by weight are given relative to the total amount of the composition being described. As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Described herein is a cosmetic composition containing Swertia japonica extract, hyaluronic acid and a retinoid. Also disclosed herein is a method for improving the appearance of fine lines and wrinkles and smoothing the skin by topically applying the cosmetic composition to the skin.

[0009] Swertia chiretta extract Swertia japonica, also known as Swertia japonica, is an ancient Ayurvedic herb that produces four sloping green-yellow flowers with a purple tint. It is native to the Himalayan ranges and is found in the high altitude foothills. The main component of the extract contains swerthiamarin, which belongs to the iridoid family of molecules typically found in medicinal plants. The extract of Swertia japonica stimulates the proliferation of keratinocytes to regenerate thin epidermis and improve the appearance of aged and wrinkled skin. It has been found to have anti-aging properties through a biomimetic pathway to reduce the appearance of wrinkles, especially vertical wrinkles. The mechanism of action is based on stem cell therapy using intercellular communication between adipose-derived stem cells (ADSC) and keratinocytes through the action of growth factors that auto-renew the skin, Swertia japonica releases these growth factors that have been shown to promote keratinocyte proliferation, resulting in a thicker epidermis with a greater number of keratinocyte layers. The resulting thicker epidermis fills in existing wrinkles due to a resurfacing effect. In an exemplary embodiment, the Swertia japonica extract is a Swertia japonica leaf extract. An exemplary embodiment of the Swertia japonica extract contains a relatively large amount of Swertiamarin, for example at least 80%, at least 85% or at least 90% Swertiamarin. As an alternative to the Swertia japonica extract, Swertiamarin can be added. Thus, as used in the compositions described herein, the Swertia japonica extract and Swertiamarin are used interchangeably, and the ingredients can be added as the Swertia japonica extract or as Swertiamarin.

[0010] In an embodiment of the present invention, the cosmetic composition contains about 0.005% to about 0.5% by weight of Swertia japonica extract (or Swertiamarin). For example, the composition may contain about 0.005% to about 0.10% by weight, 0.01% to about 0.1% by weight, about 0.005% to about 0.050% by weight, or 0.015% to about 0.040% by weight of Swertia japonica extract (or Swertiamarin). In an exemplary embodiment, the composition may contain about 0.005%, about 0.010%, about 0.015%, about 0.020%, about 0.025%, about 0.030%, about 0.035%, about 0.040%, about 0.045%, or about 0.050% by weight of Swertia japonica extract (or Swertiamarin). In a preferred embodiment, the composition contains about 0.030% by weight Swertia japonica extract (or Swertiamarin). An exemplary source of the Swertia japonica extract is SWT-7™ available from Lucas Meyer Cosmetics (Paris, FR). SWT-7 is a formulation containing Swertia japonica extract that contains a high amount of Swertiamarin and is titrated to 1.25% Swertiamarin. SWT-7™ is sold as a water-soluble powder (SWT-7™ H) and as a fat-soluble liquid (SWT-7™ L). In an exemplary embodiment of the present invention, the Swertia japonica extract is added as SWT™-7H. This Swertia japonica extract is also described in U.S. Patent Application Publication No. 2017 / 0020796, which is incorporated herein by reference in its entirety.

[0011] Hyaluronic acid According to the present invention, the terms "hyaluronic acid" and "HA" refer to both the free acid and any pharma- ceutically acceptable salts thereof, such as sodium hyaluronate, including, but not limited to, alkali metal salts, such as potassium hyaluronate and sodium hyaluronate. According to the present invention, HA can be derived from any source, including but not limited to synthetic and natural sources. Previously, HA was extracted from rooster combs. However, this ancient method has faced increasing concerns over the use of animal-derived ingredients in biomedical, pharmaceutical and cosmetic applications. HA can also be produced via fermentation with streptococci, which results in lower production costs, less environmental pollution, and produces a mixture of HA with different molecular weights. Other recent HA production processes include recombinant production from Gram-positive and Gram-negative bacteria, such as Bacillus sp., Lactococcos lactis, Agrobacterium sp. and Escherichia coli. Furthermore, recombinant microorganisms such as Bacillus and E. coli are endotoxin-free, which makes them a safe alternative source of HA products. HA with different molecular weights can be obtained by selective production methods that yield specific molecular weight ranges or by controlled hydrolysis of higher molecular weight HA.

[0012] According to the present invention, the HA used in the composition may be linear, cross-linked, or cross-linked with other components. Typically, the HA has a molecular weight of about 1 kDa to about 20,000 kDa. In one embodiment of the present invention, the composition contains one or more HAs having a molecular weight of about 1 kDa to about 2000 kDa. The HA may be present in a single molecular weight range or as a mixture of HAs exhibiting different molecular weight ranges. The HA may have a low molecular weight range, e.g., less than about 50 kDa, a medium molecular weight range, e.g., about 50 kDa to about 1000 kDa, or a high molecular weight range, e.g., greater than about 1000 kDa. The HA used in the composition of the present invention may be in a single molecular weight range, i.e., low molecular weight range HA, medium molecular weight range HA, or high molecular weight range HA, or may be a mixture of two or more of low molecular weight range HA, medium molecular weight range HA, and high molecular weight range HA. The HA of different molecular weight ranges can be added as individual commercially available compositions of a particular molecular weight range that can be added individually, or as a premix, or can be provided as a commercially available mixture of HA having different molecular weights. A preferred embodiment of the invention uses a mixture of low, medium and high molecular weight range HA.

[0013] An exemplary source of HA is BP-Triluronic™ Acid, which is a combination of three different HAs of different molecular weights: 1) high molecular weight HA having a molecular weight of about 1500 kDa to about 2000 kDa; 2) medium molecular weight HA having a molecular weight of about 300 kDa to about 500 kDa; and 3) low molecular weight HA having a molecular weight of about 12 kDa to about 15 kDa. Another exemplary source of HA is HyaCare® Filler CL, which is crosslinked HA with a 3D network structure. Another exemplary source of HA is the hyaluronic acid from EES Cosmetic Solutions, which contains HA having a molecular weight ranging from about 5 kDa to about 11 kDa. In an embodiment of the present invention, the cosmetic composition contains about 0.001% to about 2.0% by weight of HA from one or more sources. In an embodiment of the present invention, the composition contains about 0.001% to about 2.0% by weight, about 0.001% to about 1.5% by weight, about 0.001% to about 1.0% by weight, about 0.001% to about 0.5% by weight, about 0.001% to about 0.1% by weight, about 0.001% to about 0.075% by weight, or about 0.001% to about 0.050% by weight of HA. In another embodiment of the present invention, the composition contains about 0.001% to about 0.050% by weight of HA. In an embodiment of the invention, the composition contains about 0.001% HA by weight, about 0.005% HA by weight, about 0.010% HA by weight, about 0.015% HA by weight, about 0.020% HA by weight, about 0.025% HA by weight, about 0.030% HA by weight, about 0.035% HA by weight, about 0.040% HA by weight, about 0.045% HA by weight or about 0.050% HA by weight. A preferred embodiment of the composition contains about 0.002% HA by weight or about 0.050% HA by weight.

[0014] Retinoids Retinoids are a class of compounds that are derivatives and analogues of vitamin A and are used in cosmetics and medicines to regulate epithelial cell growth and treat photoaging and skin wrinkling. Four types of retinoid production are commonly recognized: • First produced retinoids, such as retinol, retinal, tretinoin (i.e., retinoic acid or retin-A), isotretinoin, and alitretinoin. • Second generation retinoids, such as etretinate and its metabolite acitretin. • Third generation retinoids, such as adapalene, bexarotene and tazarotene. • Fourth generation retinoids, e.g. trifarotene. Among known retinoids, retinol is highly recommended by dermatologists to help slow down the signs of skin aging and maintain a youthful appearance.Retinol is the form of vitamin A that occurs naturally in human skin.When used regularly in topical treatment, retinol can help improve skin firmness, visually suppress the appearance of fine lines and deep wrinkles, and even help minimize the appearance of dark circles around the eyes and around the eyes.

[0015] Any retinoid can be used in the disclosed compositions and methods, with retinol being preferred. In an embodiment of the present invention, the cosmetic composition contains about 0.005% to about 1.00% by mass of a retinoid, about 0.010% to about 0.50% by mass of a retinoid, about 0.050% to about 0.150% by mass of a retinoid, or about 0.070% to about 0.110% by mass of a retinoid. In an embodiment of the present invention, the composition contains about 0.050% by mass of a retinoid, about 0.060% by mass of a retinoid, about 0.070% by mass of a retinoid, about 0.080% by mass of a retinoid, about 0.090% by mass of a retinoid, about 0.100% by mass of a retinoid, about 0.110% by mass of a retinoid, about 0.120% by mass of a retinoid, about 0.130% by mass of a retinoid, about 0.140% by mass of a retinoid, or about 0.150% by mass of a retinoid. In an exemplary embodiment, the composition contains about 0.070% or about 0.110% by weight of a retinoid. Preferably, the retinoid is retinol.

[0016] Cosmetic Composition In one embodiment, the cosmetic composition comprises Swertia japonica extract (or Swertiamarin), hyaluronic acid and a retinoid. The cosmetic composition contains other active ingredients, excipients and solvents as further described below. Certain chromenone derivatives have been shown to exhibit certain anti-aging benefits. U.S. Patent No. 8,518,986 teaches chromenone derivatives of formula (I), or salts thereof, the entire contents of which are incorporated by reference.

[0017] [ka] (In the formula, R 1 and R 2 are the same or different, H, -(C=O)-R 7 , -C(=O)-OR 7 , linear or branched C 1 -C 20 -alkyl group, where alkyl is selected from the group consisting of oxygen, linear or branched C 3 -C 20 -Alkenyl group, linear or branched C 1 -C 20 -hydroxyalkyl or di- or polyhydroxyalkyl groups, the hydroxyl groups being attached to a primary or secondary carbon atom of the alkyl, the alkyl being optionally interrupted at least once by oxygen, C 3 -C 10 -Cycloalkyl group and C 3 -C 12 -Cycloalkenyl group (cyclic group is -CH 2 ) n -group, n=1 to 3), R 3 is H or linear or branched C 1 -C 20 -alkyl group, R4 is H or -OR 8 and R 5 and R 6 are the same or different, H or -OH, linear or branched C 1 -C 20 - an alkyl group (wherein the alkyl group may be interrupted at least once by oxygen), linear or branched C 3 -C 20 -Alkenyl group, and linear or branched C 1 -C 20 -hydroxyalkyl groups, wherein the hydroxyl group is attached to a primary or secondary carbon atom of the alkyl, and the alkyl may be interrupted at least once by oxygen; R7 is H, linear or branched C 1 -C 20 -alkyl group, where alkyl is selected from the group consisting of oxygen, linear or branched C 3 -C 20 -Alkenyl group, and linear or branched C 1 -C 20 -hydroxy-alkyl or di- or polyhydroxyalkyl groups, the hydroxyl groups being attached to a primary or secondary carbon atom of the alkyl, the alkyl being optionally interrupted at least once by oxygen, R 8 is H or linear or branched C 1 -C 20 -alkyl group)

[0018] The chromenones of formula (I) effectively enhance the topical efficacy of retinoids. Preferred compounds of formula (I) for use in the methods, HA compositions or retinoid compositions of the present invention include compounds 1-11 shown below. [ka] JPEG2025508911000005.jpg6795 JPEG2025508911000006.jpg10295 JPEG2025508911000007.jpg11295

[0019] In some embodiments, the cosmetic composition may further comprise a chromenone of formula (I). When a chromenone of formula (I) is used, the amount of water is reduced to an amount corresponding to the amount of chromenone added. When present, the cosmetic composition contains about 0.1% to about 2.0% by weight of the chromenone of formula (I). For example, the cosmetic composition may contain about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2.0% by weight of the chromenone of formula (I). Preferably, when present, the cosmetic composition contains about 0.1% by weight of the chromenone of formula (I). Preferably, the chromenone of formula (I) is one of compounds 1-11 above. Most preferably, the chromenone is compound 1, also known as dihydroxymethylchromenone.

[0020] In any embodiment, the composition may contain vitamin C compounds, such as vitamin C, analogs, derivatives and precursors that form vitamin C in cosmetic formulations or function similarly to vitamin C. The vitamin C compounds may be added directly or as extracts known to be rich in vitamin C compounds. Exemplary vitamin C compounds include 3-O-ethyl ascorbic acid; ascorbic acid; ascorbyl isostearate; ascorbyl glucoside; ascorbyl palmitate; magnesium ascorbyl phosphate; sodium ascorbyl phosphate; trisodium ascorbyl palmitate phosphate; ascorbyl methylsilanol pectin; ascorbyl aminopropyl phosphate; potassium ascorbyl tocopheryl phosphate; ascorbyl tetrahexyldecanoate; tetrahexyldecyl ascorbate; and 3-glyceryl ascorbate. Extracts known to be rich in vitamin C compounds include, but are not limited to, extracts of Terminalia ferdinandiana (i.e., Kakadu plum); Myrciaria dubia (i.e., camu camu); Malpighia emarginata (i.e., acerola cherry); Averrhoa carambola (i.e., carambola / star fruit); and rose hips. Other suitable compounds useful as vitamin C compounds include free radical scavengers, oxygen scavengers, and chelating agents. The vitamin C compound may be present in an amount of from about 0.01% to about 30% by weight, such as from about 0.1% to about 5% or about 1% by weight.

[0021] Any embodiment of the present invention may include one or more solvents and dermatological excipients known to be useful in the manufacture of cosmetic compositions. a. Emulsifiers, including nonionic, cationic, anionic or polymeric emulsifiers. b. Rheology modifiers. C. Wetting agents. d. Surfactants, including nonionic, cationic, and anionic surfactants. e. Emollients. f. pH adjusters and buffers. g.Antimicrobial agents. h. Fragrances, including, for example, fruit or plant extracts in the form of fragrances or essential oils. i. Additional antioxidants. j. Additional skin care anti-aging / anti-wrinkle agents. k. Film formers. l. FD&C Colors

[0022] The embodiment of the present invention also includes a solvent. In an exemplary embodiment, more than about 60% of the composition includes one or more solvents. The solvent includes water and water-soluble solvents, as well as water-immiscible solvents. Water and water-soluble solvents include, for example, alcohols, such as ethanol, propanol, isopropanol, glycerin, and mixtures thereof. Water-immiscible solvents include oils and waxes. As used herein, oils are water-insoluble solvents, such as mineral oils, vegetable oils, and silicone oils, such as dimethicone and cyclomethicone. In an exemplary embodiment, the composition includes water and / or water-soluble solvents, as well as oils and / or water-immiscible solvents. According to the present invention, the composition can be an emulsion, for example an oil-in-water emulsion or a water-in-oil emulsion. The oil in the emulsion can be a carbon or hydrocarbon-based oil or a silicone-based oil, i.e. a silicone emulsion. The composition can also be a solution in water or oil, for example an aqueous solution or a suspension. An exemplary oil-in-water emulsion contains about 60% to about 90% by weight of purified water and water-soluble components, and about 10% to about 40% by weight of components that form a water-immiscible or oil phase. "Purified water" is water that does not contain ingredients that may be harmful or cause adverse reactions to a subject, such as human skin. Distilled water and / or deionized water may be used.

[0023] In an exemplary embodiment, the composition is a serum or cream. As used herein, serum refers to a product that is rapidly absorbed and migrates into the deeper layers of the skin. Serums typically have a light, low-viscosity, non-greasy finish and a high concentration of active ingredients. In some embodiments, the composition comprises at least about 60% water by weight. In some embodiments, the composition is an oil-in-water emulsion. use In one aspect, the present invention discloses a method of reducing fine lines and wrinkles and smoothing the skin by topically administering to the skin a cosmetic composition containing an extract of Swertia chiretta, hyaluronic acid and a retinoid as described herein. According to the present invention, the combination of Swertia chiretta extract, hyaluronic acid and retinoids work synergistically together to reduce the appearance of fine lines and wrinkles, including vertical lines also known as "11 lines", measured both immediately after application (i.e., within 5 minutes or after the product is absorbed into the skin) and over a longer period of time. Test subjects showed fine lines and wrinkles that were lifted and filled in within approximately 5 minutes of applying the cosmetic composition to the skin (see FIG. 1). After 4 weeks of application, test subjects showed improvement in the appearance of difficult-to-treat wrinkles and visible improvement in skin texture (see FIG. 2). In fact, after 8 weeks, test subjects saw an effective reversal of 10 years of wrinkles. An additional benefit of the cosmetic composition is its ability to fill wrinkles quickly and efficiently, avoiding the use of needles and pain associated with typical injectable fillers. Furthermore, injectable fillers are costly and require regular visits to a qualified medical practitioner. Furthermore, the results of these fillers are entirely dependent on the practitioner's skill, and the results may not consistently meet patient expectations. Thus, cosmetic compositions provide synergistic or complementary benefits when used in combination with injectable fillers.

[0024] In some embodiments, fine lines and wrinkles that may be targeted for reduction include those on the forehead, lips, brow, under the eyes, nasolabial folds, and crow's feet. In some embodiments, the cosmetic composition is applied to cleansed skin of the face and / or neck. In some embodiments, the method involves applying the cosmetic composition in the morning (ie, AM) and / or in the evening (ie, PM). In one exemplary embodiment, the cosmetic composition of the present invention is applied to skin at least once a day, preferably twice a day. When applied twice a day, it is preferred to administer once in the morning and once at night. The formulation is applied by massaging into skin with fingers. After application, the formulation is absorbed into skin.

[0025] A single application was found to improve skin quality, but repeated use further improved results.Similarly, repeated application (once or twice a day) develops improvements in skin quality.A visible and measurable improvement in skin quality was observed immediately after a single application, and improved when used twice a day for one week and twice a day for four weeks.

[0026] Additional non-limiting exemplary embodiments include the following. 1. A cosmetic composition comprising Swertia japonica extract, hyaluronic acid and a retinoid. 2. The cosmetic composition of embodiment 1, wherein the composition comprises about 0.005% by weight to about 0.500% by weight of Swertia japonica extract. 3. The cosmetic composition of embodiment 1 or 2, wherein the composition comprises from about 0.005% to about 1.00% by weight of a retinoid. 4. The cosmetic composition of any one of embodiments 1 to 3, wherein the composition comprises from about 0.001% by weight to about 2.0% by weight of hyaluronic acid. 5. The cosmetic composition of any one of embodiments 1 to 4, wherein the composition comprises about 0.005% by mass to about 0.500% by mass of Swertia japonica extract, about 0.005% by mass to about 1.00% by mass of a retinoid, and about 0.001% by mass to about 2.0% by mass of hyaluronic acid. 6. The cosmetic composition of any one of embodiments 1-5, wherein the composition comprises about 0.030% by weight of Swertia japonica extract, about 0.070% by weight of a retinoid, and about 0.050% by weight of hyaluronic acid. 7. The cosmetic composition of any one of embodiments 1-6, wherein the composition comprises about 0.030% by weight of Swertia japonica extract, about 0.110% by weight of a retinoid, and about 0.002% by weight of hyaluronic acid.

[0027] 8. The cosmetic composition of any one of embodiments 1-7, wherein the retinoid is selected from the group consisting of retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene and tazarotene, and trifarotene. 9. The cosmetic composition of any one of embodiments 1-8, wherein the retinoid is retinol. 10. The cosmetic composition of any one of embodiments 1-9, wherein the hyaluronic acid comprises a mixture of hyaluronic acid of different molecular weights. 11. The cosmetic composition of any one of embodiments 1 to 10, wherein the mixture comprises at least three types of hyaluronic acid of different molecular weights. 12. The cosmetic composition of any one of embodiments 1 to 11, further comprising a vitamin C compound. 13. The cosmetic composition of any one of embodiments 1-12, wherein the vitamin C compound comprises ascorbic acid or 3-O-ethyl ascorbic acid.

[0028] 14. The cosmetic composition of any one of embodiments 1 to 13, further comprising a chromenone of formula (I) or a salt thereof. [ka] (In the formula, R1 and R2 are identical or different and are selected from the group consisting of H, -(C=O)-R7, -C(=O)-OR7, linear or branched C1-C20-alkyl groups, where the alkyl may be interrupted at least once by oxygen, linear or branched C3-C20-alkenyl groups, linear or branched C1-C20-hydroxyalkyl or di- or polyhydroxyalkyl groups, where the hydroxyl group is bonded to a primary or secondary carbon atom of the alkyl, where the alkyl may be interrupted at least once by oxygen, C3-C10-cycloalkyl groups and C3-C12-cycloalkenyl groups (cyclic groups may be bridged by -CH2)n- groups, where n=1 to 3); R3 is H or a linear or branched C1-C20-alkyl group, R4 is H or -OR8; R5 and R6 are identical or different and are selected from the group consisting of H or -OH, linear or branched C1-C20-alkyl groups, which may be interrupted at least once by oxygen, linear or branched C3-C20-alkenyl groups, and linear or branched C1-C20-hydroxyalkyl groups, in which the hydroxyl group is bonded to a primary or secondary carbon atom of the alkyl, which may be interrupted at least once by oxygen; R7 is selected from the group consisting of H, linear or branched C1-C20-alkyl groups, the alkyl being optionally interrupted at least once by oxygen, linear or branched C3-C20-alkenyl groups, and linear or branched C1-C20-hydroxy-alkyl or -di- or polyhydroxyalkyl groups, the hydroxyl groups being bonded to primary or secondary carbon atoms of the alkyl, the alkyl being optionally interrupted at least once by oxygen, R8 is H or a linear or branched C1-C20-alkyl group.

[0029] 15. The cosmetic composition of embodiment 14, wherein the cosmetic composition comprises from about 0.1% to about 2.0% by weight of the compound of formula (I). 16. The cosmetic composition of embodiment 14 or 15, wherein the compound of formula (I) is dihydroxymethylchromenone. 17. The cosmetic composition of any one of embodiments 1-16, wherein the cosmetic composition comprises at least 60% by weight of water. 18. The cosmetic composition of any one of embodiments 1-16, wherein the cosmetic composition is a cream or serum. 19. A method for reducing fine lines and / or wrinkles and / or smoothing the skin, comprising topically administering to the skin a cosmetic composition of any one of embodiments 1-18.

[0030] 20. The method of embodiment 19, wherein the skin is facial and / or neck skin. 21. The method of embodiment 19, wherein the cosmetic composition is applied to the forehead, lips, between the eyebrows, under the eyes, nasolabial folds, crow's feet, or a combination thereof. 22. The method of any one of embodiments 19-21, wherein the skin is cleansed skin. 23. The method of any one of embodiments 19-22, wherein the cosmetic composition is applied in the morning, in the evening, or both. 24. A method for improving skin properties in a subject, comprising topically administering to the subject a cosmetic composition of any one of embodiments 1-18 in an amount sufficient to improve one or more skin properties. 25. The method according to embodiment 24, wherein the cosmetic composition is administered in an amount sufficient to reduce fine lines and / or wrinkles in the forehead by 5% to 50%, as determined by image analysis. 26. The method according to embodiment 24 or 25, wherein the cosmetic composition is administered in an amount sufficient to reduce fine lines and / or wrinkles at the crow's feet by 5% to 50%, as determined by image analysis.

[0031] 27. The method according to any one of embodiments 24-26, wherein the cosmetic composition is administered in an amount sufficient to improve skin plumping by 7% to 25%, as determined by image analysis. 28. The method according to any one of embodiments 24-27, wherein the cosmetic composition is administered in an amount sufficient to increase skin firmness as determined by a 20% to 80% decrease in Cutometer R0 measurement. 29. The method according to any one of embodiments 24-28, wherein the cosmetic composition is administered in an amount sufficient to increase skin elasticity as determined by a 15% to 50% increase in Cutometer R2 measurement. 30. The method according to any one of embodiments 24-29, wherein the cosmetic composition is administered once. 31. The method according to any one of embodiments 24-29, wherein the cosmetic composition is administered twice a day for at least 1 week, at least 4 weeks, or at least 8 weeks. 32. A cosmetic composition according to any one of embodiments 1 to 18, for use in improving one or more skin properties of a subject.

[0032] 33. A cosmetic composition according to any one of embodiments 1 to 18 for use in reducing fine lines and / or wrinkles in the forehead by 5% to 50%, as determined by image analysis. 34. A cosmetic composition according to any one of embodiments 1 to 18 for use in reducing fine lines and / or wrinkles at the crow's feet by 5% to 50%, as determined by image analysis. 35. A cosmetic composition according to any one of embodiments 1 to 18, for use in improving skin plumping by 7% to 25%, as determined by image analysis. 36. A cosmetic composition according to any one of embodiments 1 to 18, for use in increasing skin firmness as determined by a 20% to 80% reduction in Cutometer R0 measurement. 37. A cosmetic composition according to any one of embodiments 1-18 for use in increasing skin elasticity, as determined by a 15% to 50% increase in Cutometer R2 measurement. EXAMPLES

[0033] The following examples are provided for illustrative purposes only and are intended to be purely exemplary of the present disclosure and are not intended to limit the scope of the present invention. Example 1 Table 1 is an exemplary general formula for the composition of the present invention. All weights are in weight percent unless otherwise specified. [Table 1]

[0034] Example 2 Table 2 is an exemplary formulation of a skin cream according to an embodiment of the present invention. All weights are in weight percent unless otherwise specified. [Table 2] TIFF2025508911000011.tif45169

[0035] Example 3 Table 3 is an exemplary formulation of a skin serum composition according to an embodiment of the present invention. All weights are in weight percent unless otherwise specified. [Table 3] TIFF2025508911000013.tif116169

[0036] Example 4 Example 4 provides details regarding testing of the skin serum composition of Example 3. Subject Selection: Subjects were enrolled according to the following inclusion / exclusion criteria: Inclusion criteria 1. Women aged 35 to 65 (inclusive) in good general health (no medical check-up required). 2. Individuals with fine lines across the face and wrinkles in the forehead area) a score of "5" (marked) or above (for eligibility purposes only). 3. Individuals who indicate a willingness to participate in the study, follow instructions, and remain in the study for a total of 8 weeks of the study period. 4. Individuals who were able to read, understand, and sign the informed consent form. 5. Individuals who were regular users of retinol.

[0037] Exclusion criteria 1. Women who are pregnant, planning to become pregnant, breastfeeding and / or nursing. 2. Individuals who had any visible skin disease. 3. Individuals who had sunburn or tan on their forearms or who planned to travel with sun exposure or use a tanning booth during the course of the study. 4. Individuals who were simultaneously involved in a research project for a product involving the face / neck area. 5. Individuals who were taking medications that may interfere with the study results, including use of steroidal / nonsteroidal anti-inflammatory drugs or antihistamines, Accutane, or any type of prescription acne medication. 6. Individuals who had acne, active atopic dermatitis / eczema or psoriasis. 7. Treatment or history of cancer of any type. 8. Individuals undergoing treatment for asthma or diabetes. 9. Individuals with known sensitivity to cosmetics or personal care products. 10. Individuals who have not been on any of the surfaces in the past 14 days. 11. Individuals who have had any punctures on the face. 12. Individuals with any tattoos on the face or neck (except for thin liner on the upper eyelash line [no winged eyeliner]). 13. Individuals who did not intend to remove jewelry (earrings) prior to being photographed.

[0038] Test procedure The study was an 8-week study preceded by a 1-week washout period. During the study period, the test product was used by each of the subjects according to the instructions for use. Subjects reported to the study site to begin the washout phase. Subjects were qualified by trained technicians prior to filling out paperwork. Once qualified, subjects were instructed to fill out paperwork and wash their face with Cetaphil® soap for one week. Following a one-week washout period, subjects reported to the study facility for a baseline visit without using any personal care products or cosmetics on their face.Facial irritation assessment for safety purposes was performed by trained technicians.Trained technicians took digital images of each subject using a Visia CR® Imaging System (Canfield Scientific, Fairfield, NJ).Images were analyzed using ImagePro® software (MediaCybernetics, Bethesda, MD) to determine the changes (if any) in fine lines and wrinkles on the forehead, fine lines / wrinkles at the crow's feet, and skin plumping. Trained technicians also performed Cutometer® (Courage+Khazaka, Germany) measurements on each subject's face (to measure skin tautness and elasticity). Subjects completed their first application of the test product at the testing facility under the supervision of a trained technician. Immediately after application, all measurements were repeated, including Visia photography and professional photography. Subjects completed a questionnaire. Subjects were then given the test product and a daily diary. Subjects returned to the study facility after 1, 4, and 8 weeks of use for additional photographs and Cutometer® measurements. At each visit, subjects completed a questionnaire.

[0039] Baseline assessment All subjects reported to the study site for the baseline visit with a freshly washed "clean face" (no makeup on the face / eye area or any skin care products applied to the face). Subjects were assessed for eligibility by trained technicians. At the baseline visit, visual assessments were performed, digital photographs were taken, and Cutometer® measurements were taken. Evaluations were performed according to protocol. Subjects were sent home with the test product and a diary and instructed to: Instruction: This journal must include the following: 1. The date and time (AM and PM) the product was used. 2. Any comments or observations made while using the product. 3. Do not use any other serums or new skin care / cosmetics during the testing procedure. 4. Apply product according to instructions below. Instructions: After cleansing skin, apply a thin layer directly onto lines & wrinkles in the AM and PM. Continue with the next steps of your skin care regimen: Apply an SPF 15 or higher sunscreen during the day while using this product.

[0040] Test Procedure (cont.) 1, 4 and 8 week evaluations Subjects were instructed to return to the study facility after 1, 4, and 8 weeks of product use for additional digital photography, irritation assessments, and Cutometer® measurements. All subjects completed a questionnaire at each visit. Clinical Evaluation Procedures Evaluation of all parameters was performed according to the scales and procedures outlined below. Assessment of lines and wrinkles in the forehead At the baseline visit only (for eligibility purposes), a trained technician assessed each subject's forehead for fine lines and wrinkles according to the following scale: A scale for scoring fine lines / wrinkles in the forehead 0=No fine lines / wrinkles 1-3 = Mild fine lines / wrinkles 4-6 = Prominent fine lines / wrinkles 7-9 = Very pronounced fine lines / wrinkles

[0041] Assessment of fine lines / wrinkles around the eyes At the Baseline visit only (for eligibility purposes), a trained technician assessed the appearance of fine lines / wrinkles in each subject according to the following scale: Scale for scoring fine lines / wrinkles around the eyes 0 = no fine streaks 1-3 = Mild fine streaks 4-6 = prominent fine streaks 7-9 = Very pronounced fine streaks Assessment of skin bulge At the baseline visit only (for eligibility purposes), a trained technician assessed the skin turgor on each subject's face according to the following scale: Scale for scoring skin turgor 0 = Very noticeable skin swelling 1-3 = noticeable skin swelling 4-6 = Mild skin swelling 7-9 = No skin bulge / flat appearance

[0042] Stimuli evaluation At baseline, immediately after application, and after 1, 4, and 8 weeks, a trained technician rated each subject's face for stimulation according to the following scale: This evaluation was for safety purposes only and was not used to determine efficacy. Scale for scoring stimuli 0 = no stimulus present + = Barely perceptible stimuli are present 1 = Mild irritation present 2 = Moderate irritation present 3 = Significant stimulation present 4 = Severe irritation present

[0043] Digital photography procedures and analysis At baseline, immediately after application, and at 1, 4 and 8 weeks, digital images of the face are taken from the front, right and left sides.At each evaluation, digital images of the face of each subject are taken from the front, right and left sides using Visia CR® 2.2 (Canfield Scientific, Fairfield, New Jersey).To ensure consistency between photos, each subject wears a black T-shirt or wears a disposable black cloth around the shoulders to eliminate the appearance of clothing in the photo, and each subject wears a black headband to pull hair away from and away from the face.Images are analyzed using Image Pro® software (MediaCybernetics, Bethesda, MD) to determine the changes (if any) in the appearance of fine lines and wrinkles in the forehead, fine lines / wrinkles at the crow's feet, and bulging skin. Fine lines and wrinkles in the forehead - Image analysis Fine lines and wrinkles in the skin are detected using standard illumination or a fixed angular orientation light source (cross polarized light at a fixed angle) and then analyzed as a mean area score, a reduction in this score represents an improvement in the appearance of fine lines & wrinkles in the forehead area.

[0044] Fine Lines and Wrinkles around the Eyes - Image Analysis Fine lines and wrinkles in the skin are detected using standard illumination or a fixed angular orientation light source (cross polarized light at a fixed angle) and then analyzed as a mean area score, a reduction in this score represents an improvement in the appearance of crow's feet fine lines & wrinkles. Skin swelling - Image analysis To determine changes in skin turgor, the width of all wrinkles present on the face was measured. A decrease in the mean wrinkle score represented improvement; an increase represented deterioration. Cutometer® Measurement At baseline, immediately after the first application, and at 1, 4, and 8 weeks, trained technicians performed Cutometer® measurements. Skin elasticity was measured on each subject's face using the Cutometer® R2 parameter. An increase in Cutometer® R2 measurement indicated an improvement (increase) in skin elasticity. A decrease represented a deterioration. Skin firmness was measured on each subject's face using the Cutometer® R0 parameter. A decrease in the Cutometer® R0 measurement indicated an improvement (increase) in skin firmness. An increase represented a deterioration.

[0045] Consumer Perception Evaluation At each visit, subjects completed a questionnaire. When completing the questionnaire, subjects were provided with a full-face mirror to examine their face while answering the questions. statistical analysis All data points collected were compared to each subject's baseline for differences between time points. Data collected from discontinued subjects may not have been included in statistical analyses. The sum of differences was analyzed using the Wilcoxon signed rank test. Responses were considered statistically significant from baseline if the p-value was ≦0.05.

[0046] Results and Discussion Thirty-three female subjects, ages 44-65, were listed for the study. A total of 31 subjects (31 / 33) successfully completed the study. Subjects No. 27 and 33 were discontinued for reasons unrelated to the conduct of the study. Forehead fine lines / wrinkles - Image analysis At baseline, immediately after the first application, and after 1, 4, and 8 weeks of product use, trained technicians took digital images of each subject's face using a Visia CR® imaging system. Using ImagePro® software, the images were analyzed to determine the change (if any) in the appearance of fine lines / wrinkles on the forehead. A reduction in the mean area score represents an improvement (or reduction) in the appearance of fine lines / wrinkles on the forehead.

[0047] The table below provides a summary of the image analysis of forehead fine lines / wrinkles. [Table 4] When images taken immediately after first application and after 1, 4, and 8 weeks of product use were compared to baseline images, a mean improvement of 9.3%, 14.2%, 23.7%, and 26.3%, respectively, occurred based on image analysis. The improvements were highly significant compared to baseline. A total of 97%, 100%, 100%, and 97% of subjects showed improvement immediately after first application and after 1, 4, and 8 weeks of use, respectively.

[0048] Fine Lines / Wrinkles around the Eyes - Image Analysis At baseline, immediately after the first application, and after 1, 4, and 8 weeks of product use, a trained technician took digital images of each subject's face using a Visia CR® imaging system. Using ImagePro® software, the images were analyzed to determine the change (if any) in the appearance of crow's feet fine lines / wrinkles. A reduction in the mean area score represents an improvement (or reduction) in the appearance of crow's feet fine lines / wrinkles. The following table provides a summary of the image analysis of crow's feet fine lines / wrinkles. [Table 5] When images taken immediately after first application and after 1, 4, and 8 weeks of product use were compared to baseline images, a mean improvement of 11.5%, 19.8%, 29.1%, and 31.7%, respectively, occurred based on image analysis. The improvements observed were highly significant compared to baseline. A total of 94%, 100%, 94%, and 100% of subjects showed improvement immediately after first application and after 1, 4, and 8 weeks of use, respectively.

[0049] Skin swelling - Image analysis At baseline, immediately after first application, and after 1, 4, and 8 weeks of use, trained technicians took digital images of each subject using a Visia CR® imaging system. Using ImagePro® software, the skin was analyzed for uniformity and changes in skin bulging were determined. A reduction in score indicates improvement. The following table provides a summary of the image analysis of skin bulging. [Table 6] When images taken immediately after first application and after 1, 4, and 8 weeks of product use were compared to baseline images, a mean improvement of 4.2%, 5.2%, 13.1%, and 13.1%, respectively, occurred based on image analysis. The improvements observed were statistically significant compared to baseline. A total of 68%, 68%, 97%, and 97% of subjects showed improvement immediately after application and after 1, 4, and 8 weeks of use, respectively.

[0050] Cutometer® RO Evaluation At baseline, immediately after application, and after 1, 4, and 8 weeks of product use, a trained technician performed Cutometer® RO measurements on each subject's face to measure skin firmness. A decrease in the measurement indicates an improvement (increase) in skin firmness. [Table 7] When measurements taken immediately after application and after 1, 4, and 8 weeks of product use were compared to baseline measurements, there was a mean worsening of 6.6% and 20.9%, and a mean improvement of 11.5% and 47.3%, based on Cutometer® RO measurements, respectively. The improvements were highly significant compared to baseline at the 8-week visit. A total of 52%, 33%, 61%, and 84% of subjects showed improvement immediately after application and after 1, 4, and 8 weeks of use, respectively.

[0051] Cutometer® R2 Evaluation At baseline, immediately after application, and after 1, 4 and 8 weeks of using the product, trained technicians performed Cutometer® R2 measurements on each subject's face to measure skin elasticity.Increasing measurements indicate improvements in skin elasticity.The following table provides a summary of Cutometer® R2 evaluations. [Table 8] When measurements taken immediately after application and after 1, 4 and 8 weeks of product use were compared to baseline measurements, there was a mean improvement of 23.8%, 24.8%, 28.2% and 31.4%, respectively, based on Cutometer® R2 measurements. The changes were highly significant compared to baseline. A total of 94%, 93%, 100% and 100% of subjects showed improvement immediately after application and after 1, 4 and 8 weeks of use, respectively.

[0052] Skin Irritation - Engineer's Evaluation At baseline, immediately after first use, and after 1, 4, and 8 weeks of product use, trained technicians rated each subject's face against the stimuli. [Table 9] There was no irritation observed in any subject during the course of the study.

[0053] Answers to the questionnaire Subjects were required to complete a questionnaire immediately after application, and after 1, 4, and 8 weeks of product use. Figures 3-6 summarize the responses to the questionnaire at time point 0, which corresponds to immediately after the first application. Immediately after application, subjects were required to complete a questionnaire. The following table provides a summary of the questionnaire responses for the test products. [Table 10] TIFF2025508911000021.tif92170 The majority of subjects (52%-97%) answered affirmatively to some of the questions about various attributes of the product immediately after first use. A total of 97% of subjects either very much thought or thought that the product dispensed the correct amount.

[0054] After one week of product use, subjects were required to complete a questionnaire. The following table provides a summary of the questionnaire responses for the test products. [Table 11] TIFF2025508911000023.tif92170 The majority of subjects (52%-97%) answered affirmatively to most questions about various attributes of the product after one week of using the product. A total of 97% of subjects either very much thought or thought the product dispensed the correct amount.

[0055] After 4 weeks of product use, subjects were required to complete a questionnaire. The following table provides a summary of the questionnaire responses for the test products. [Table 12] TIFF2025508911000025.tif93155 The majority of subjects (52%-100%) answered affirmatively to most questions about the various attributes of the product after 4 weeks of using the product. All of the subjects very much or somewhat thought that the packaging was easy to use and handle.

[0056] After 8 weeks of product use, subjects were required to complete a questionnaire. The following table provides a summary of the questionnaire responses for the test products. [Table 13] TIFF2025508911000027.tif93155 The majority of subjects (58%-100%) responded affirmatively to nearly all questions about the various attributes of the product after 8 weeks of using the product. All of the subjects very much or somewhat thought that the package dispensed the correct amount.

[0057] Summary and Conclusion A clinical efficacy and consumer perception study was conducted on 31 subjects to determine whether the cosmetic composition according to Example 3 improved various parameters of the skin. Skin plumping was significantly improved based on image analysis immediately after application and after 1, 4 and 8 weeks of product use. Fine lines / wrinkles around the eyes were significantly improved based on image analysis immediately after application and after 1, 4 and 8 weeks of product use. Fine lines / wrinkles on the forehead were significantly improved based on image analysis immediately after application and after 1, 4 and 8 weeks of product use.

[0058] Skin firmness was significantly improved based on Cutometer measurements after 8 weeks of product use. Skin elasticity was significantly improved based on Cutometer measurements immediately after application and after 1, 4 and 8 weeks of product use. The product did not cause any irritation in any of the subjects during the course of the study. The product had a fairly low level of subject acceptance immediately after first use, a moderate level of subject acceptance after one week of product use, and a fairly high level of subject acceptance after four and eight weeks of product use, with the majority of subjects responding affirmatively to all questions about the various attributes of the product's performance. While preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present disclosure. It should be understood that various substitutes for the embodiments of the present disclosure described herein may be used in the practice of the present disclosure. It is intended that the following claims define the scope of the present disclosure, and that methods and structures thereof that are within the scope of such claims, and their equivalents, be covered thereby.

Claims

1. A cosmetic composition comprising an extract of Swertia chirata, hyaluronic acid and a retinoid.

2. 2. The cosmetic composition of claim 1, wherein the composition comprises from about 0.005% to about 0.500% by weight of Swertia japonica extract.

3. The cosmetic composition of claim 1 , wherein the composition comprises from about 0.005% to about 1.00% by weight of a retinoid.

4. The cosmetic composition of claim 1 , wherein the composition comprises from about 0.001% to about 2.0% by weight of hyaluronic acid.

5. 2. The cosmetic composition of claim 1, wherein the composition comprises from about 0.005% to about 0.500% by weight of Swertia cratae extract, from about 0.005% to about 1.00% by weight of a retinoid, and from about 0.001% to about 2.0% by weight of hyaluronic acid.

6. 2. The cosmetic composition of claim 1, wherein the composition comprises about 0.030% by weight of Swertia chiretta extract, about 0.070% by weight of a retinoid, and about 0.050% by weight of hyaluronic acid.

7. 2. The cosmetic composition of claim 1, wherein the composition comprises about 0.030% by weight of Swertia chiretta extract, about 0.110% by weight of a retinoid, and about 0.002% by weight of hyaluronic acid.

8. A cosmetic composition according to any one of claims 1 to 7, wherein the retinoid is selected from the group consisting of retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene and tazarotene, and trifarotene.

9. The cosmetic composition according to claim 8, wherein the retinoid is retinol.

10. A cosmetic composition according to any one of claims 1 to 9, wherein the hyaluronic acid comprises a mixture of hyaluronic acids of different molecular weights.

11. 11. The cosmetic composition of claim 10, wherein the mixture comprises at least three types of hyaluronic acid of different molecular weights.

12. The cosmetic composition according to any one of claims 1 to 11, further comprising a vitamin C compound.

13. The cosmetic composition of claim 12, wherein the vitamin C compound comprises ascorbic acid or 3-O-ethyl ascorbic acid.

14. A cosmetic composition according to any one of claims 1 to 13, further comprising a chromenone of formula (I) or a salt thereof. 【Chemistry 1】 (In the formula, R 1 and R 2 are the same or different and are H, -(C=O)-R 7 , -C(=O)-OR 7 , linear or branched C 1 -C 20 - alkyl group, where alkyl is selected from the group consisting of oxygen, linear or branched C 3 -C 20 -Alkenyl group, linear or branched C 1 -C 20 -hydroxyalkyl or di- or polyhydroxyalkyl groups, the hydroxyl groups being attached to a primary or secondary carbon atom of the alkyl, the alkyl being optionally interrupted at least once by oxygen, C 3 -C 10 -Cycloalkyl group and C 3 -C 12 -Cycloalkenyl group (cyclic group is -CH 2 ) n -group, n=1 to 3), R 3 is H or linear or branched C 1 -C 20 is an alkyl group, R4 is H or -OR 8 and R 5 and R 6 are the same or different, H or -OH, linear or branched C 1 -C 20 - an alkyl group (wherein the alkyl group may be interrupted at least once by oxygen), linear or branched C 3 -C 20 -Alkenyl group, and linear or branched C 1 -C 20 - hydroxyalkyl groups, the hydroxyl group being attached to a primary or secondary carbon atom of the alkyl, which may be interrupted at least once by oxygen, R 7 is H, linear or branched C 1 -C 20 - alkyl group, where alkyl is selected from the group consisting of oxygen, linear or branched C 3 -C 20 -Alkenyl group, and linear or branched C 1 -C 20 -hydroxy-alkyl or -di- or polyhydroxyalkyl groups, the hydroxyl groups being attached to a primary or secondary carbon atom of the alkyl, the alkyl being optionally interrupted at least once by oxygen, R 8 is H or linear or branched C 1 -C 20 -alkyl group)

15. The cosmetic composition of claim 14, wherein the cosmetic composition comprises from about 0.1% to about 2.0% by weight of the compound of formula (I).

16. 16. A cosmetic composition according to claim 14 or 15, wherein the compound of formula (I) is dihydroxymethylchromenone.

17. The cosmetic composition according to any one of claims 1 to 16, wherein the cosmetic composition comprises at least 60% by weight of water.

18. The cosmetic composition according to any one of claims 1 to 16, which is a cream or serum.

19. 20. A method for reducing fine lines and / or wrinkles and / or smoothing the skin, comprising the step of topically administering to the skin a cosmetic composition according to any one of claims 1 to 18.

20. 20. The method of claim 19, wherein the skin is facial and / or neck skin.

21. 20. The method of claim 19, wherein the cosmetic composition is applied to the forehead, lips, between the eyebrows, under the eyes, nasolabial folds, crow's feet, or combinations thereof.

22. 20. The method of claim 19, wherein the skin is cleansed skin.

23. 20. The method of claim 19, wherein the cosmetic composition is applied in the morning, in the evening, or both.

Images